Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 1/20 | 0.47 |
| ▸ | LIMK1 | P53667 | 7/20 | 0.45 |
| ▸ | LIMK2 | P53671 | 7/20 | 0.45 |
| ▸ | CDK9 | P50750 | 2/20 | 0.45 |
| ▸ | GRM1 | Q13255 | 5/20 | 0.43 |
| ▸ | GRM5 | P41594 | 4/20 | 0.43 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30595928 | 0.99 | TNK2 (0.47) | TNK2LIMK1LIMK2CDK9GRM1 | |
| SCHEMBL30595948 | 0.98 | TNK2 (0.47) | TNK2LIMK1LIMK2CDK9GRM1 | |
| SCHEMBL24074603 | 0.89 | TNK2 (0.47) | TNK2LIMK1LIMK2CDK9GRM1 | |
| SCHEMBL30595965 | 0.88 | CDK9 (0.47) | TNK2LIMK1LIMK2CDK9GRM1 | |
| SCHEMBL30595936 | 0.88 | TNK2 (0.44) | TNK2LIMK1LIMK2CDK9GRM1 | |
| SCHEMBL30595929 | 0.87 | TNK2 (0.45) | TNK2LIMK1LIMK2CDK9GRM1 | |
| SCHEMBL30595923 | 0.83 | LIMK1 (0.64) | TNK2LIMK1LIMK2CDK9GRM1 | |
| SCHEMBL4008367 | 0.78 | LIMK1 (0.51) | TNK2LIMK1LIMK2 | |
| SCHEMBL30595935 | 0.78 | LIMK1 (0.59) | TNK2LIMK1LIMK2 | |
| SCHEMBL30595921 | 0.78 | LIMK1 (0.51) | TNK2LIMK1LIMK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4157844-B1 | 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER | CENTRE NAT RECH SCIENT (FR) | 2024-07-10 | — | — | EP | disclosed |
| US-20230312576-A1 | 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER | UNIVERSITÉ DE TOURS (FR) | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312576-A1 | 4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-3,6-DIHYDROPYRIDINE-1-(2H)-CARBOXAMIDE DERIVATIVES AS LIMK AND/OR ROCK KINASES INHIBITORS FOR USE IN THE TREATMENT OF CANCER | LIMK1, LIMK2, ROCK1 | TNK2 31/4885LIMK1 1/4885LIMK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.